These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 15857120

  • 1. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC, Jones ML, Gunn DE, Geraci LS, Jones JH, Sawicki DR, Sredy J, Jacot JL, Dicioccio AT, Petrova T, Mitschler A, Podjarny AD.
    J Med Chem; 2005 May 05; 48(9):3141-52. PubMed ID: 15857120
    [Abstract] [Full Text] [Related]

  • 2. Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC, Sibley EO, McCann EE, Combs KJ, Flam B, Sawicki DR, Sabetta A, Carrington A, Sredy J, Howard E, Mitschler A, Podjarny AD.
    Bioorg Med Chem; 2004 Nov 01; 12(21):5661-75. PubMed ID: 15465344
    [Abstract] [Full Text] [Related]

  • 3. Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC, Doan B, Sawicki DR, Sredy J, Podjarny AD.
    Bioorg Med Chem Lett; 2009 Apr 01; 19(7):2006-8. PubMed ID: 19250825
    [Abstract] [Full Text] [Related]

  • 4. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
    Ashizawa N, Yoshida M, Sugiyama Y, Akaike N, Ohbayashi S, Aotsuka T, Abe N, Fukushima K, Matsuura A.
    Jpn J Pharmacol; 1997 Feb 01; 73(2):133-44. PubMed ID: 9074947
    [Abstract] [Full Text] [Related]

  • 5. Naphtho[1,2-d]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors.
    Da Settimo F, Primofiore G, La Motta C, Sartini S, Taliani S, Simorini F, Marini AM, Lavecchia A, Novellino E, Boldrini E.
    J Med Chem; 2005 Nov 03; 48(22):6897-907. PubMed ID: 16250648
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE, Cotter MA, Basso M, Hohman TC.
    Diabetologia; 1997 Mar 03; 40(3):271-81. PubMed ID: 9084964
    [Abstract] [Full Text] [Related]

  • 7. A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications.
    Karasova MJ, Prnova MS, Stefek M.
    Pharmazie; 2014 Oct 03; 69(10):747-51. PubMed ID: 25985564
    [Abstract] [Full Text] [Related]

  • 8. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
    Negoro T, Murata M, Ueda S, Fujitani B, Ono Y, Kuromiya A, Komiya M, Suzuki K, Matsumoto J.
    J Med Chem; 1998 Oct 08; 41(21):4118-29. PubMed ID: 9767647
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats.
    Matsui T, Nakamura Y, Ishikawa H, Matsuura A, Kobayashi F.
    Jpn J Pharmacol; 1994 Feb 08; 64(2):115-24. PubMed ID: 8028228
    [Abstract] [Full Text] [Related]

  • 10. Substituted derivatives of indole acetic acid as aldose reductase inhibitors with antioxidant activity: structure-activity relationship.
    Juskova M, Majekova M, Demopoulos V, Stefek M.
    Gen Physiol Biophys; 2011 Dec 08; 30(4):342-9. PubMed ID: 22131315
    [Abstract] [Full Text] [Related]

  • 11. Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
    Kotani T, Nagaki Y, Ishii A, Konishi Y, Yago H, Suehiro S, Okukado N, Okamoto K.
    J Med Chem; 1997 Feb 28; 40(5):684-94. PubMed ID: 9057855
    [Abstract] [Full Text] [Related]

  • 12. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA, Cameron NE, Hohman TC.
    J Peripher Nerv Syst; 1998 Feb 28; 3(3):217-23. PubMed ID: 10959252
    [Abstract] [Full Text] [Related]

  • 13. Effects of a new aldose reductase inhibitor on various tissues in vitro.
    Terashima H, Hama K, Yamamoto R, Tsuboshima M, Kikkawa R, Hatanaka I, Shigeta Y.
    J Pharmacol Exp Ther; 1984 Apr 28; 229(1):226-30. PubMed ID: 6423811
    [Abstract] [Full Text] [Related]

  • 14. In vitro inhibition of lens aldose reductase by (2-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-8-yl)-acetic acid in enzyme preparations isolated from diabetic rats.
    Djoubissie PO, Snirc V, Sotnikova R, Zurova J, Kyselova Z, Skalska S, Gajdosik A, Javorkova V, Vlkovicova J, Vrbjar N, Stefek M.
    Gen Physiol Biophys; 2006 Dec 28; 25(4):415-25. PubMed ID: 17356233
    [Abstract] [Full Text] [Related]

  • 15. Reduced nerve blood flow in diabetic rats: relationship to nitric oxide production and inhibition of aldose reductase.
    Tomlinson DR, Dewhurst M, Stevens EJ, Omawari N, Carrington AL, Vo PA.
    Diabet Med; 1998 Jul 28; 15(7):579-85. PubMed ID: 9686698
    [Abstract] [Full Text] [Related]

  • 16. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
    Malamas MS, Hohman TC, Millen J.
    J Med Chem; 1994 Jun 24; 37(13):2043-58. PubMed ID: 8027986
    [Abstract] [Full Text] [Related]

  • 17. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
    Hotta N, Koh N, Sakakibara F, Nakamura J, Hamada Y, Wakao T, Hara T, Mori K, Naruse K, Nakashima E, Sakamoto N.
    J Pharmacol Exp Ther; 1996 Jan 24; 276(1):49-55. PubMed ID: 8558455
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.
    Fresneau P, Cussac M, Morand JM, Szymonski B, Tranqui D, Leclerc G.
    J Med Chem; 1998 Nov 19; 41(24):4706-15. PubMed ID: 9822541
    [Abstract] [Full Text] [Related]

  • 20. [Effect of gui xin tong on sorbitol and nerve conduction velocity in diabetic rats].
    Liang X, Hao W, Jia L, Xu H, Zhang K, Guo S, Zhang H, Sun R.
    Zhongguo Zhong Yao Za Zhi; 1999 Dec 19; 24(12):749-51, 765. PubMed ID: 12205986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.